NICE guidance reinforces treatment drugs
Final clinical guidance recommends timely referrals for AMD and its treatment
Pharmaceutical company Bayer has welcomed the conclusions published in the National Institute for Health and Care Excellence’s (NICE) final clinical guidance on age-related macular degeneration (AMD).
The guidance, which was published this week, reinforces the value of Eylea, also known as aflibercept, as well as Lucentis, for the treatment of wet AMD.
It also makes recommendations for the timely referral of patients with the sight-threatening condition.
It highlights that urgent referrals to macular services for people with suspected wet AMD should be made in one working day, with those who have the disease confirmed waiting no longer than 14 days for treatment.
Medical director for ophthalmology at Bayer, Dr Jackie Napier said: “Bayer strongly believes that all patients with wet AMD should receive timely access to sight-preserving treatment with a licensed medicine within the NHS. We are encouraged by the provision of this guideline giving the clinical community the reassurance of having access to rigorously tested products to effectively treat this ageing and vulnerable population.”
Eylea is currently licensed in the UK for the treatment of wet AMD, visual impairment due to macular oedema secondary to central retinal vein occlusion and visual impairment due to macular oedema secondary to branch retinal vein occlusion. It is also used for visual impairment due to diabetic macular oedema and myopic choroidal neovascularisation.